CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-06 | Callos Andrew EVP, Chief Commercial Officer | Sale | −3,341 | $43.27 | $145K | 64,434 |
| 2025-03-06 | Malik Fady Ibraham EVP Research & Development | Sale | −8,228 | $43.27 | $356K | 105,394 |
| 2025-03-06 | Blum Robert I President & CEO | Sale | −16,970 | $43.44 | $737K | 364,181 |
| 2025-03-05 | Blum Robert I President & CEO | Sale 10b5-1 | −25,000 | $43.23 | $1.1M | 381,151 |
| 2025-03-04 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 118,071 |
| 2025-03-04 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $42.50 | $85K | 116,071 |
| 2025-03-04 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 31,105 | ||
| 2025-03-04 | Harrington Robert Arthur Director | Sale 10b5-1 | −900 | $42.50 | $38K | 15,108 |
| 2025-03-03 | Malik Fady Ibraham EVP Research & Development | Sale | −2,449 | $42.88 | $105K | 113,622 |
| 2025-03-03 | Callos Andrew EVP, Chief Commercial Officer | Sale | −1,114 | $42.88 | $48K | 67,775 |
| 2025-03-03 | Blum Robert I President & CEO | Sale | −8,743 | $42.88 | $375K | 406,151 |
| 2025-02-18 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 118,071 |
| 2025-02-18 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $45.98 | $92K | 116,071 |
| 2025-02-18 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 33,105 | ||
| 2025-02-10 | Landry Robert E Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +25,538 | 25,538 | ||
| 2025-02-04 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 118,071 |
| 2025-02-04 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $48.06 | $96K | 116,071 |
| 2025-02-04 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 35,105 | ||
| 2025-01-21 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 118,071 |
| 2025-01-21 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $45.92 | $92K | 116,071 |
Page 23 of 33 · 660 trades